

References

1. World Health Organization (WHO). "Solidarity" clinical trial for COVID-19 treatments. Geneva: WHO; 2020 [cited 2020 22 July]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments>
2. Inserm. Launch of a European clinical trial against COVID-19 (22 March 2020). [Internet]. Inserm; 2020 [cited 2020 20 April]. Available from: <https://presse.inserm.fr/en/launch-of-a-european-clinical-trial-against-covid-19/38737/>
3. Randomised evaluation of COVID-19 therapy (RECOVERY). Available from: <https://www.recoverytrial.net/>
4. World Health Organization. Therapeutics and COVID-19: living guideline Geneva: WHO; 2021 [updated 24 September 2021]. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.3>
5. World Health Organization (WHO). Corticosteroids for COVID-19: Living Guidance Geneva: WHO; 2020 [updated 2 September 2020]. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1>
6. W. H. O. Rapid Evidence Appraisal for COVID-19 Therapies Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Oct 6;324(13):1330-41.
7. Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, Lorrot M, et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA. 2021;325(9):855-64.
8. Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al. Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes. N Engl J Med. 2021 Jul 1;385(1):23-34.
9. World Health Organization (WHO). COVID-19 Clinical management: living guidance Geneva: World Health Organization (WHO); 2021 [updated 23 November 2021]. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2>
10. Ramakrishnan S, Nicolau DV, Jr., Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021 Apr 9.
11. Agarwal A, Rochwerf B, Siemieniuk RA, Agoritsas T, Lamontagne F, Askie L, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020 Sep 4;370:m3379.
12. European Medicines Agency. EMA recommends approval for use of RoActemra in adults with severe COVID-19 Amsterdam: EMA; 2021. Available from: <https://www.ema.europa.eu/en/news/ema-recommends-approval-use-roactemra-adults-severe-covid-19>
13. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 Mar 4;384(9):795-807.
14. European Medicines Agency. EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients requiring supplemental oxygen Amsterdam: EMA; 2021. Available from: <https://www.ema.europa.eu/en/news/ema-starts-evaluating-use-olumiant-hospitalised-covid-19-patients-requiring-supplemental-oxygen>
15. Tharaux P-L, Pialoux G, Pavot A, Mariette X, Hermine O, Resche-Rigon M, et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021;9(3):295-304.
16. Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021 Oct;27(10):1752-60.
17. European Medicines Agency. EMA starts evaluating the use of Kineret in adult COVID-19 patients at increased risk of severe respiratory failure Amsterdam: EMA; 2021. Available from: <https://www.ema.europa.eu/en/news/ema-starts-evaluating-use-kineret-adult-covid-19-patients-increased-risk-severe-respiratory-failure>
18. European Medicines Agency. COVID-19: EMA recommends authorisation of two monoclonal antibody medicines Amsterdam: EMA; 2021. Available from: <https://www.ema.europa.eu/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines>
19. U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19: FDA; 2021. Available from: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19>
20. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med. 2021 Oct 7;385(15):1382-92.
21. Eli Lilly and Company. Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents 2021 [updated January 21 2021]. Available from: <https://investor.lilly.com/news-releases/news-release-details/lillys-neutralizing-antibody-bamlanivimab-ly-cov555-prevented>

22. Cohen MS, Nirula A, Mulligan MJ, Novak RM, Marovich M, Yen C, et al. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. *JAMA*. 2021 Jul 6;326(1):46-55.
23. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature*. 2021 May;593(7857):130-5.
24. European Medicines Agency. Bamlanivimab and etesevimab for COVID-19: Withdrawal from the rolling review process Amsterdam: EMA; 2021. Available from: <https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/bamlanivimab-etesevimab-covid-19>
25. European Medicines Agency. EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19 Amsterdam: EMA; 2021. Available from: <https://www.ema.europa.eu/en/news/ema-issues-advice-use-sotrovimab-vir-7831-treating-covid-19>
26. U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19: FDA; 2021. Available from: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19>
27. AstraZeneca. Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19: AstraZeneca; 2021. Available from: <https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html>
28. AstraZeneca. AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US 2021. Available from: <https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/azd7442-request-for-emergency-use-authorization-for-covid-19-prophylaxis-filed-in-us.html>
29. Celltrion Healthcare Co. Ltd. Celltrion submits Marketing Authorisation Application to the European Medicines Agency for regdanvimab (CT-P59) Incheon: Celltrion Healthcare; 2021. Available from: https://www.celltrionhealthcare.com/en-us/board/newsdetail?modify_key=529&pagenumber=1&keyword=&keyword_type=
30. W. H. O. Solidarity Trial Consortium, Pan H, Peto R, Henaó-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021 Feb 11;384(6):497-511.
31. *British Medical Journal (BMJ)*. WHO Guideline Development Group advises against use of remdesivir for covid-19 2020 [updated 19 November 2020]. Available from: <https://www.bmj.com/company/newsroom/who-guideline-development-group-advises-against-use-of-remdesivir-for-covid-19/>
32. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med*. 2020 Oct 8.
33. Spinner CD, Gottlieb RL, Criner GJ, Arribas Lopez JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. *JAMA*. 2020 Sep 15;324(11):1048-57.
34. European Medicines Agency (EMA). First COVID-19 treatment recommended for EU authorisation [Internet]. Amsterdam: EMA; 2020 [updated 25 June 2020; cited 2021 20 April]. Available from: <https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation>
35. Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. *Lancet Infect Dis*. 2021 Sep 14.
36. European Commission. Daily News 03 / 07 / 2020: European Commission authorises first treatment against COVID-19 [Internet]. Brussels: European Commission; 2020 [cited 2020 22 July]. Available from: https://ec.europa.eu/commission/presscorner/detail/en/mex_20_1266
37. U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use [Internet]. Silver Spring: FDA; 2020 [updated 15 June 2020; cited 2021 20 April]. Available from: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-warns-newly-discovered-potential-drug-interaction-may-reduce>
38. U.S. National Library of Medicine. Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19) (CARAVAN) 2020 [cited 2021 20 April]. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT04431453>
39. Mozaffari E, Chandak A, Zhang Z, Liang S, Thrun M, Gottlieb RL, et al. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. *Clin Infect Dis*. 2021 Oct 1.
40. Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. *Nat Microbiol*. 2021 Jan;6(1):11-8.
41. Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M, Dinnon KH, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. *Nature*. 2021 2021/03/01;591(7850):451-7.

42. BusinessWire. Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir 2021 [updated 6 March 2021; cited 2021 20 April]. Available from: <https://www.businesswire.com/news/home/20210305005610/en/>
43. Merck Sharp & Dohme Corp. Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVE-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19: Merck; 2021. Available from: <https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/>
44. Merck Sharp & Dohme Corp. Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study 2021. Available from: <https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderate-covid-19-in-positive-interim-analysis-of-phase-3-study-2021/>
45. European Medicines Agency. EMA issues advice on use of Lagevrio (molnupiravir) for the treatment of COVID-19 Amsterdam: EMA; 2021. Available from: <https://www.ema.europa.eu/en/news/ema-issues-advice-use-lagevrio-molnupiravir-treatment-covid-19>
46. Pfizer Inc. Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death: Pfizer; 2021. Available from: <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results>
47. European Medicines Agency. EMA starts review of Paxlovid for treating patients with COVID-19 Amsterdam: EMA; 2021.
48. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. *Clin Infect Dis*. 2021 Aug 2;73(3):531-4.
49. Udwardia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. *Int J Infect Dis*. 2021 2021/02/01/;103:62-71.
50. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. *J Clin Invest*. 2020 Sep 1;130(9):4791-7.
51. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. *Nat Med*. 2020 Nov;26(11):1708-13.
52. Simonovich VA, Burgos Pratz LD, Scibona P, Beruto MV, Vallone MG, Vazquez C, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. *N Engl J Med*. 2021 Feb 18;384(7):619-29.
53. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). *BMJ*. 2020;371:m3939.
54. Recovery Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. *Lancet*. 2021 May 29;397(10289):2049-59.
55. Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. *The Cochrane database of systematic reviews*. 2021 May 20;5(5):CD013600.
56. World Health Organization (WHO). WHO recommends against the use of convalescent plasma to treat COVID-19 Geneva: WHO; 2021. Available from: <https://www.who.int/news/item/07-12-2021-who-recommends-against-the-use-of-convalescent-plasma-to-treat-covid-19>
57. Tardif J-C, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19. *medRxiv*2021.
58. Institut de Cardiologie de Montreal. Colchicine reduces the risk of COVID-19-related complications 2021 [cited 2021 20 April]. Available from: <https://www.icm-mhi.org/en/pressroom/news/colchicine-reduces-risk-covid-19-related-complications>
59. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet Respiratory Medicine*. 2021;9(12):1419-26.
60. BioSpace. SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function BioSpace2021 [cited 2021 20 April]. Available from: <https://www.biospace.com/article/releases/sarpac-clinical-trial-of-leukine-sargramostim-rhu-gm-csf-in-hospitalized-covid-19-patients-meets-primary-endpoint-of-significant-improvement-in-lung-function/>
61. U.S. National Library of Medicine. Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC) (SARPAC) 2020 [updated 2 March 2021; cited 2021 20 April]. Available from: <https://clinicaltrials.gov/ct2/show/NCT04326920>
62. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis*. 2020 Jul 28;71(15):732-9.
63. Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. *Ann Intern Med*. 2020 Jul 16;0(0):null.

64. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med*. 2020 Aug 6;383(6):517-25.
65. World Health Organization (WHO). Therapeutics and COVID-19: Living Guideline Geneva: WHO; 2021 [updated 31 March 2021]. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1>
66. Kelland K. Global COVID-19 Prevention Trial of Hydroxychloroquine to Resume. *Medscape*. 2020.
67. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med*. 2020 May 7;382(19):1787-99.
68. Recovery Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*. 2020 Oct 5.
69. National Institutes of Health (NIH). COVID-19 Treatment Guidelines: Ivermectin 2021 [cited 2021 20 April]. Available from: <https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/ivermectin/>
70. López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. *JAMA*. 2021;325(14):1426-35.
71. Gonzalez JLB, González Gámez M, Enciso EAM, Maldonado RJE, Hernández Palacios D, Dueñas Campos S, et al. Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial. *medRxiv2021*.
72. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. *Clin Microbiol Infect*. 2021 Jan;27(1):83-8.
73. Musuuza J, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and super-infection with SARS-CoV-2 and other pathogens: A Systematic Review and Meta-analysis. *medRxiv2020*.
74. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clin Microbiol Infect*. 2020 Dec;26(12):1622-9.
75. Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. *Pneumonia (Nathan)*. 2021;13(1):5.
76. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. *PLoS One*. 2021;16(5):e0251170.
77. Clancy CJ, Schwartz IS, Kula B, Nguyen MH. Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. *Open forum infectious diseases*. 2021 Mar;8(3):ofab065.
78. Butler CC, Dorward J, Yu L-M, Gbinigie O, Hayward G, Saville BR, et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet*. 2021;397(10279):1063-74.
79. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA*. 2020;323(24):2493-502.
80. Furtado RHM, Berwanger O, Fonseca HA, Correa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. *Lancet*. 2020 Oct 3;396(10256):959-67.
81. Langford BJ, So M, Raybardhan S, Leung V, Soucy JR, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. *Clin Microbiol Infect*. 2021 Apr;27(4):520-31.
82. Nori P, Cowman K, Chen V, Bartash R, Szymczak W, Madaline T, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. *Infect Control Hosp Epidemiol*. 2021 Jan;42(1):84-8.